Menu
ncarol.com
  • Home
  • Music
  • Asheville Music
  • Entertainment
  • Real Estate
  • Business
  • Technology
  • Health
  • Artificial Intelligence
ncarol.com

Eppin Pharma Receives $300,000 Grant for Male Contraception
ncarol.com/10037375

Trending...
  • Orlando Real Estate Broker Bent Danholm Wins 2026 Goody Business Book Award for The Architecture of Demand
  • Massive Acquisition Into Defense With STS for Virtuix Holdings; $40 Million Revenue Business Will Accelerate Growth Transforming Market Position
  • Commercial Sales for U.S.-Made, Preservative-Free Ketamine Amid Long-Runnin Shortage Following FDA Approval by NRx Pharmaceuticals, Inc
MCI's total commitment to male contraception now exceeds $3M USD since 2017

DURHAM, N.C. - ncarol.com -- Male Contraceptive Initiative (MCI), a private non-profit foundation, announced four grants, including a grant to Eppin Pharma Inc to support research and development of a male contraceptive, raising MCI's total commitment to male contraception to over $3M USD since 2017.

Eppin Pharma will receive $300,000 to aid in their work developing a novel form of male contraception. Eppin Pharma's product, EP055, is a hormone-free method of contraception that is quickly moving to first-in-human studies. EP055 inhibits sperm motility that is crucial for fertility. The drug is intended to be administered as a pill to men on a daily or on-demand basis, providing protection from pregnancy.

With over $3 million invested in male contraceptive product development, MCI seeks to push male contraceptive research projects towards commercialization. There are a variety of male contraceptive research projects in the drug development pipeline; from early stage screening of drugs to studies that pave the way for early clinical trials, and consistent with their mission, MCI focuses their funding on promising projects within this pipeline like Eppin Pharma's EP055. MCI's mission is to facilitate research and development of male contraceptives for people around the world, and to build awareness among researchers, donors and the general public about the demand for and status of novel male contraceptive methods.

More on ncarol.com
  • Nious Media Expands Gaming Coverage With 2026 Game & Geek Expo Special
  • UK Financial Ltd Launches MayaSwap On MAYA CHAIN To Facilitate UKFLMS-For-Gold Swaps, Officially Transforming UKFLMS From Meme Into A Real-World Asset
  • The Dark Chocolate Nutcracker Marks 15 Years
  • Entrepreneur Nouho M Kanneh Talks Family, Faith and a $37 Million Portfolio in New Interview
  • Emerald Williams Selected to Super Lawyers Rising Stars 2022-2026

Through its funding efforts, MCI has championed this mission in manifold ways: investing in promising product development through this and other rounds of funding, supporting students and young professionals through fellowships and travel grants, and consistently advocating with the public and media for an increased method mix that includes male contraception.

"More and more men are expressing the desire to participate in contraception with their partners. We are confident that the time is right to emphatically get behind the talent and energy in the field in order to achieve a real vision for a shared contraceptive future," said MCI Executive Director Heather Vahdat.

Dr. Michael O'Rand, CEO and Co-Founder of Eppin added – "We are grateful for the support that MCI has given us and hopeful that this investment in our technology will advance the field of male non-hormonal contraception."

https://www.malecontraceptive.org/

Contact
Kevin Shane
***@malecontraceptive.org


Source: Male Contraceptive Initiative

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on ncarol.com
  • LCH2 Awarded Additional $1 Million to Advance Lewis County Clean Energy Campus
  • Security Planning Tips For Your Holiday Event From Access Patrol Services
  • Contracting Resources Group Receives 2026 HIRE Vets Platinum Medallion Award
  • Business News & Info Goes Inside Paragon FX Group's Hunt for Original Film Props
  • Kitchen Table Economics: An Invitation to Think Differently
  • Gabby Press Earns High Praise From BookLife For Book About the Dangers of Corporate AI
  • Win a $5,000 VIP Family Experience at the 100th Thanksgiving Day Parade in New York City
  • CB Stuffer Announces Private Sale to Secure Future of Brand Growth
  • The Fifth Annual "Bamboo Lantern Festival" to Illuminate Tokyo Mizumachi and Sumida River Walk®
  • Apex Wellness Architect Hosts Intimate Tea & Intentions Tea Bar Experience to Close Out the Year
  • Iglesia.com Positioned in Multimillion-Dollar Domain Market with $10 Million Asking Price
  • TCA VG: 2025 Funding Climbs to $9M across 43 Companies; Cumulative Returns Reach 5.3 MOIC & 22% IRR
  • Searching for the Next LBE Creator: CalArts Launches First-Ever D.R.E.A.M.S. Pitch Competition
  • Integris Composites Joins International Sea Power Conference Aboard HMS Prince of Wales
  • Lake Norman Philharmonic Annual Holiday Concert 2026
  • Commercial Sales Launch Following FDA Approval; National Sales Force Now in Action as January Shipments and Major Market Opportunity Take Shape
  • ViewDNS.info Launches Monitors, Alerting Teams the Moment Something Changes on Their Domains
  • Philadelphia-Area Entrepreneur Nouho M Kanneh Builds $37 Million Net Worth Across Real Estate, E-Commerce and Retail
  • Contracting Resources Group Named a 2027 Elev8 GovCon Honoree by OrangeSlices
  • The World's No.1 Superstar® Brings Christmas Back in Grand Style with Music, Cinematic Glamour, and Luxury Fashion
_catLbl0 _catLbl1

Popular on ncarol.com

  • Nious Media Expands Independent Entertainment Network Through Gaming, Music and Digital Storytelling - 210
  • North Carolina Author Carrie Sybert Celebrates Three Published Books - 192
  • Kestrel Ridge Health Launches AI-Powered Ophthalmology Workforce Forecasting Platform - 183
  • OncoBeta Introduces Rhenium-SCT for Non-Melanoma Skin Cancer at Theageneio Cancer Hospital of Thessaloniki - 133
  • 450 Million Revenue Run Rate, Global Telecom Reach and a New Digital Growth Opportunity Take Center Stage: IQSTEL, Inc. (N A S D A Q: IQST) - 123
  • Arizona Pest Control Surpasses $200,000 in Contributions to Southern Arizona High School Sports and Education Programs - 122
  • Bacchus Wine & Spirits and Michelin Guide–Recommended Ethel's Fancy to Host Exclusive LOUIS XIII Limited Edition Diwali Decanter Celebration - 119
  • Unlocking the Next Phase of Growth with New AI Innovations; Targeting 2027 as Breakeven; Revenue Momentum Accelerates: ZenaTech (N A S D A Q: ZENA) - 113
  • KayeDinero Drops "CyberLeek" Amid GTA VI Headlines, Unveils Asheville "Barksdale" Visual - 108
  • Alan Hamilton of Shiver Hamilton Campbell Inducted as a Fellow of the American College of Trial Lawyers - 108

Similar on ncarol.com

  • Massive Acquisition Into Defense With STS for Virtuix Holdings; $40 Million Revenue Business Will Accelerate Growth Transforming Market Position
  • Commercial Sales for U.S.-Made, Preservative-Free Ketamine Amid Long-Runnin Shortage Following FDA Approval by NRx Pharmaceuticals, Inc
  • Contracting Resources Group Receives 2026 HIRE Vets Platinum Medallion Award
  • Commercial Sales Launch Following FDA Approval; National Sales Force Now in Action as January Shipments and Major Market Opportunity Take Shape
  • Contracting Resources Group Named a 2027 Elev8 GovCon Honoree by OrangeSlices
  • Qscription Technologies Welcomes Joanna Krause, MD, MRMD to Its Clinical Advisory Board
  • New Omega-3 Fish Oil Under NIH Investigation: What Makes It Different From EPA and DHA?
  • OncoBeta Introduces Rhenium-SCT for Non-Melanoma Skin Cancer at Theageneio Cancer Hospital of Thessaloniki
  • New Patient Data Show REQORSA® Activating Cellular Repair Pathways as Roche Collaboration Advances Precision Lung Cancer Strategy for Genprex, Inc
  • New TROP2 Research Breakthrough Strengthens REQORSA® Gene Therapy Story as Roche Collaboration Advances Precision Lung Cancer Treatment: Genprex, Inc
Copyright © 2026 ncarol.com | Contact Us | Privacy Policy | Terms of Service | Contribute